Altamira Therapeutics Ltd CYTO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CYTO is a good fit for your portfolio.
News
-
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
-
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
-
Thinking about buying stock in Equillium, Kuke Music, Altamira Therapeutics, MoneyHero, or Enerplus?
-
Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines
-
Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal
-
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
Trading Information
- Previous Close Price
- $1.50
- Day Range
- $1.41–1.50
- 52-Week Range
- $1.41–28.40
- Bid/Ask
- $1.44 / $1.48
- Market Cap
- $3.17 Mil
- Volume/Avg
- 46,743 / 1.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 12
Valuation
|
Metric
|
CYTO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.83 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CYTO
|
|---|---|
Quick Ratio | 0.78 |
Current Ratio | 1.38 |
Interest Coverage | −6.33 |
Quick Ratio
CYTO
Profitability
|
Metric
|
CYTO
|
|---|---|
Return on Assets (Normalized) | −223.73% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −526.69% |
Return on Assets
CYTO
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cwchfxcvc | Xjsj | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jylfthpsd | Sljzlwj | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fdkxpfcr | Djtmbm | $98.1 Bil | |
MRNA
| Moderna Inc | Yjxmqzhy | Lgs | $38.8 Bil | |
ARGX
| argenx SE ADR | Zghzgcrq | Mlsv | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Gsfnqzs | Dtc | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zjmmbqrl | Fhgsw | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Scgdwzc | Gvrrcc | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zgkzggbm | Bhdvfn | $12.5 Bil | |
INCY
| Incyte Corp | Mcfwcvbs | Fczgw | $11.9 Bil |